secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001104659-22-116496
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Therapeutics Q3 net loss narrows to $4.0M; cash $33.1M; ATRN-119 Phase 1 initiated
--------------------------------------------------------------------------------

- Net loss of $4.0M ($0.12 per share) vs $9.5M ($0.45) in Q3 2021; cash and equivalents $33.1M (down from $53.1M at Dec 2021).
- R&D expenses fell to $1.1M from $6.0M due to trial close-outs and Atrin acquisition cost reductions.
- Phase 1 trial of ATR inhibitor ATRN-119 opened for enrollment; expects 1-2 additional sites in Q4 2022.
- WEE1 inhibitor ATRN-W1051 in preclinical stage; IND-enabling studies anticipated in Q4 2022.
- APR-548 Phase 1 trial closed; no ongoing clinical trials of eprenetapopt (APR-246).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000110465922116496/0001104659-22-116496-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000110465922116496/tm2230091d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-116496

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer